English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu
A researcher at the Lausanne Branch of the Ludwig Institute for Cancer Research, Ho is a leader in the young field of immunometabolism, which explores how the chemical byproducts of metabolism mediate a molecular conversation between the immune system and the tissues it patrols. That conversation has a profound influence on tumor growth and survival and on the efficacy of conventional and immunotherapeutic interventions for the treatment of cancer. Ho’s laboratory has recently made important contributions to our understanding of how immunometabolomic effects alter the behavior of immune cells like macrophages and dendritic cells in tumors and disrupt the T cell response to cancer that is essential to immunotherapy.
Ho joined Ludwig Lausanne in 2015, following a postdoctoral appointment in the laboratory of Susan Kaech, who was then at Yale University and with whom he conducted pioneering research in the field. In addition to his Ludwig post, Ho is a tenured associate professor at the University of Lausanne.
About Ludwig Cancer Research
Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for 48 years. Ludwig combines basic science with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested $2.7 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers. To learn more, visit www.ludwigcancerresearch.org.
For further information please contact Rachel Reinhardt, [email protected] or +1-212-450-1582.
Original post https://alertarticles.info
